EarlyTect Colon Cancer Test

Overview

The EarlyTect Colorectal Cancer Test is an advanced genetic screening tool designed to detect colorectal cancer at its earliest stages. Utilizing cancer-specific aberrant methylation patterns, this test offers a non-invasive, highly accurate method for early cancer detection.

Key Features

• Non-Invasive Sample Collection: EarlyTect requires only a small stool sample (1-2 grams), making the screening process convenient and comfortable. Samples are collected at hospitals, where insurance may cover the procedure.
• High Sensitivity and Specificity: With 90% sensitivity and 90% specificity, EarlyTect delivers reliable results regardless of clinical stage, tumor location, sex, or age.
• Quick Turnaround Time: Receive results within 5 days, ensuring prompt follow-up and consultation with your healthcare provider.
• FDA Approved: Approved by the Thai FDA and patented in several major countries worldwide, EarlyTect is a trusted and validated screening tool.
• Insurance Coverage: While the test is likely to be covered by insurance, patients should consult their doctors and insurance companies to confirm coverage.
• Wide Usage: EarlyTect is widely used in Korea, demonstrating its reliability and acceptance in the medical community.

Benefits

• Early Detection: Identifies colorectal cancer in its early stages, significantly increasing the chances of successful treatment and cure.
• Convenience: Non-invasive collection method eliminates the need for fasting, colonic irrigation, or anesthesia.
• Peace of Mind: Quick and accurate results enable timely medical intervention and proactive health management.

Applications

EarlyTect is suitable for men and women aged 30 to 80, particularly those with risk factors such as age, obesity, smoking, drinking, and diabetes. It is ideal for routine screening and early detection of colorectal cancer.